Fundraising Fox
Outlook Therapeutics
NASDAQ: OTLKIselin, US · Delaware corporation · 1 known investors
Find your way into Outlook Therapeutics
252 people in our graph can introduce you to the Outlook Therapeutics team.
Sign up to see every warm intro you have to Outlook Therapeutics
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Outlook Therapeutics team. We find them
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes you can't see from your own inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Outlook Therapeutics develops ophthalmic therapies for retinal diseases, including anti-VEGF treatments for conditions such as neovascular (wet) age-related macular degeneration, diabetic macular edema, and branch retinal vein occlusion. Its lead product, LYTENAVA (bevacizumab-vikg), is an FDA-approved ophthalmic bevacizumab formulation for adults with wet AMD.
Founders & leadership
PM
Pankaj MohanFounder
LA
Lawrence A. KenyonMember of the Board of DirectorsLawrence A. Kenyon has held executive roles including CEO, CFO, and COO across multiple biotechnology and pharmaceutical companies, including Tamir Biotechnology, Par Pharmaceutical, and NeoPharm, with additional experience in financial services at Mathers & Company and Arthur Andersen. He brings over 20 years of experience in capital raising, clinical trial execution, and financial operations in the biopharmaceutical sector.
JE
Jeff EvansonChief Commercial Officer2018–2025Jeff Evanson is Executive Officer at Outlook Therapeutics, which develops ophthalmic therapies for retinal diseases including anti-VEGF treatments for wet age-related macular degeneration and diabetic macular edema. He has experience in business development, product launches, and commercialization strategy in therapeutic markets.
Board
FG
Faisal G. SukhtianBoard director
YH
Yezan HaddadinBoard director
AH
Andong HuangBoard director
KJ
Kurt J. HilzingerBoard director
JA
Julia A. HallerBoard director
GA
Gerd AuffarthBoard director
RH
Randy H. ThurmanBoard director
JG
Julian GangolliBoard director
DG
Donald GriffithBoard director
Investors · 1
Reported raises · per SEC filings
Form D private placements$181M disclosed across 11 of 13 rounds · 2015–2026
▶$5MofferedMay 2026 · 2 investors · BiotechnologyRule 506(b)
▶$5MofferedMay 2026 · 2 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Yezan HaddadinDirector
- Lawrence A. KenyonExecutive Officer, Director
- Faisal G. SukhtianDirector
- Randy H. ThurmanDirector
- Julian GangolliDirector
- Kurt J. HilzingerDirector
- Gerd AuffarthDirector
- Andong HuangDirector
- Offering amount
- $5M
- Finders' fees
- $485K
- Placement agents
- H.C. Wainwright & Co., LLC
- First sale
- Apr 2026
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$32MofferedJan 2025 · 10 investors · BiotechnologyRule 506(b)
▶$32MofferedJan 2025 · 10 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Lawrence A. KenyonExecutive Officer, Director
- Jeff EvansonExecutive Officer
- Faisal G. SukhtianDirector
- Julia A. HallerDirector
- Gerd AuffarthDirector
- Yezan HaddadinDirector
- Randy H. ThurmanDirector
- Julian GangolliDirector
- Andong HuangDirector
- Kurt J. HilzingerDirector
- Offering amount
- $32M
- Finders' fees
- $1.4M
- First sale
- Jan 2025
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$5MraisedApr 2024 · 1 investors · BiotechnologyRule 506(b)
▶$5MraisedApr 2024 · 1 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Jeff EvansonExecutive Officer
- Julia A. HallerDirector
- Julian GangolliDirector
- Gerd AuffarthDirector
- Andong HuangDirector
- C. Russell TrenaryExecutive Officer, Director
- Lawrence A. KenyonExecutive Officer, Director
- Kurt J. HilzingerDirector
- Yezan HaddadinDirector
- Randy H. ThurmanDirector
- Faisal G. SukhtianDirector
- Offering amount
- $13.3M
- Amount sold
- $5M
- First sale
- Apr 2024
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$60MraisedMar 2024 · 21 investors · BiotechnologyRule 506(b)
▶$60MraisedMar 2024 · 21 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Jeff EvansonExecutive Officer
- Andong HuangDirector
- Julia A. HallerDirector
- Kurt J. HilzingerDirector
- Lawrence A. KenyonExecutive Officer, Director
- Julian GangolliDirector
- Gerd AuffarthDirector
- Faisal G. SukhtianDirector
- Randy H. ThurmanDirector
- C. Russell TrenaryExecutive Officer, Director
- Yezan HaddadinDirector
- Offering amount
- $159M
- Amount sold
- $60M
- Finders' fees
- $3.6M
- First sale
- Mar 2024
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$1MraisedJan 2023 · 1 investors · BiotechnologyRule 506(b)
▶$1MraisedJan 2023 · 1 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Randy H. ThurmanDirector
- Andong HuangDirector
- Yezan HaddadinDirector
- Julia A. HallerDirector
- Gerd AuffarthDirector
- Julian GangolliDirector
- Lawrence A. KenyonExecutive Officer, Director
- Faisal G. SukhtianDirector
- C. Russell TrenaryExecutive Officer, Director
- Kurt J. HilzingerDirector
- Offering amount
- $1M
- Amount sold
- $1M
- First sale
- Dec 2022
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$31.8MraisedJan 2023 · 1 investors · BiotechnologyRule 506(b)
▶$31.8MraisedJan 2023 · 1 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Julia A. HallerDirector
- Andong HuangDirector
- C. Russell TrenaryExecutive Officer, Director
- Randy H. ThurmanDirector
- Julian GangolliDirector
- Lawrence A. KenyonExecutive Officer, Director
- Faisal G. SukhtianDirector
- Gerd AuffarthDirector
- Yezan HaddadinDirector
- Kurt J. HilzingerDirector
- Offering amount
- $31.8M
- Amount sold
- $31.8M
- First sale
- Dec 2022
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$4MraisedFeb 2021 · 2 investors · BiotechnologyRule 506(b)
▶$4MraisedFeb 2021 · 2 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Julian GangolliDirector
- Randy ThurmanDirector
- Yezan HaddadinDirector
- Kurt J. HilzingerDirector
- Lawrence A. KenyonExecutive Officer, Director
- Faisal G. SukhtianDirector
- Andong HuangDirector
- Gerd AuffarthDirector
- Offering amount
- $4M
- Amount sold
- $4M
- First sale
- Feb 2021
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$16MraisedJun 2020 · 1 investors · BiotechnologyRule 506(b)
▶$16MraisedJun 2020 · 1 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Julian GangolliDirector
- Kurt J. HilzingerDirector
- Randy ThurmanDirector
- Lawrence A. KenyonExecutive Officer, Director
- Jeff EvansonExecutive Officer
- Faisal G. SukhtianDirector
- Yezan HaddadinDirector
- Gerd AuffarthDirector
- Terry DagnonExecutive Officer
- Offering amount
- $16M
- Amount sold
- $16M
- First sale
- Jun 2020
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Valuation · disclosed
Disclosed events$96.8Mvaluation at IPOMay 2016 · $6.00/share · 424B4
filing ↗Source: SEC prospectus filings, and round valuations the company or its investors disclosed — follow each entry's link for the claim.
Related companies · 7
Seeking AlphaSeeking Alpha is a financial research platform offering stock analysis, market news, investment ideas, and quantitative ratings across asset classes, drawing on a large community of contributing analysts. It serves individual and professional investors seeking research and data-driven insight on stocks and markets.
NasdaqNasdaq operates a technology infrastructure platform for financial markets across three business segments: Capital Access Platforms (which includes listing services, indices, and analytics tools), Financial Technology (comprising compliance, regulatory, and capital markets software), and Market Services (equities and derivatives trading operations). The company serves financial institutions, listed companies, investment managers, and regulatory agencies globally.
RobinhoodRobinhood is a financial trading platform that enables users to manage portfolios across stocks, ETFs, cryptocurrencies, options, futures, and prediction markets. The platform serves retail investors with low barriers to entry, offering portfolio management services and market insights.
Simply Wall StSimply Wall St is an investment platform that provides financial data visualization and analysis tools for individual investors. The platform serves long-term investors globally by simplifying complex market information into visual and narrative formats to make stock investing more accessible.
TradingViewTradingView is a charting platform and social network used by over 100 million traders and investors worldwide to analyze and trade across global financial markets. The platform provides tools for technical analysis, market data, and community collaboration for retail and institutional traders.
StockTwitsStocktwits operates an online community platform where investors and traders share ideas, analysis, and trade discussions organized around stock tickers. The page presented is its community guidelines rather than a product description.
TipRanksFinancial analysis and stock research platform.
Companies working in the same space as Outlook Therapeutics.
Frequently asked questions
- What does Outlook Therapeutics do?
- Outlook Therapeutics develops ophthalmic therapies for retinal diseases, including anti-VEGF treatments for conditions such as neovascular (wet) age-related macular degeneration, diabetic macular edema, and branch retinal vein occlusion. Its lead product, LYTENAVA (bevacizumab-vikg), is an FDA-approved ophthalmic bevacizumab formulation for adults with wet AMD.
- Who founded Outlook Therapeutics?
- Outlook Therapeutics was founded by Pankaj Mohan.
- Who are Outlook Therapeutics's investors?
- Outlook Therapeutics's investors include Avoro Capital Advisors.
- How much funding has Outlook Therapeutics raised?
- Outlook Therapeutics has disclosed $181M raised across 11 of its 13 known rounds.
- Where is Outlook Therapeutics headquartered?
- Outlook Therapeutics is headquartered in Iselin, US.